Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jan 7, 2008; 14(1): 1-14
Published online Jan 7, 2008. doi: 10.3748/wjg.14.1
Table 3 Agents for anti-VEGF/VEGFR-based therapy of solid tumours
NameTargetMechanismCurrent status
Small molecule inhibitors
Sunitinib (Sutent)PDGFR, VEGFR, c-KIT, FLT-3Tyrosine kinase inhibitorApproved for advanced renal cell carcinoma and GIST (with restricted indications)[87150]
PhaseIfor HCC[151]
Zactima (ZD6474)VEGFR, EGFRTyrosine kinase inhibitorPhase III for NSCLC[156]
Phase II for thyroid cancer[157]
Vatalanib (PTK787/ZK 222584)VEGFR, PDGFR, C-KITTyrosine kinase inhibitorPhase II/III for colorectal cancer[152]
PhaseIfor HCC[153]
Anti-ligand targeting
BevacizumabVEGFVEGF-neutralizing antibodyApproved for colorectal cancer
Phase III for NSCLC[166]
Phase II for HCC[154]
VEGF trapVEGFSoluble decoy receptor which neutralizes all VEGF A isoformsPhaseIfor advanced solid tumours[155]